Search

Your search keyword '"Sandhu, Irwindeep"' showing total 284 results
Start Over Author "Sandhu, Irwindeep" Publication Year Range Last 10 years
284 results on '"Sandhu, Irwindeep"'

3. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

Author

Landgren, C, Chari, Ajai, Cohen, Yael, Spencer, Andrew, Voorhees, Peter, Estell, Jane, Sandhu, Irwindeep, Jenner, Matthew, Williams, Catherine, Cavo, Michele, van de Donk, Niels, Beksac, Meral, Moreau, Philippe, Goldschmidt, Hartmut, Kuppens, Steven, Bandekar, Rajesh, Clemens, Pamela, Neff, Tobias, Heuck, Christoph, Qi, Ming, and Hofmeister, Craig

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Smoldering Multiple Myeloma, Survival Rate
Abstract

Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules. At the prespecified primary analysis (15.8-month median follow-up), the complete response (CR) rates (co-primary endpoint) were 2.4%, 4.9%, and 0% for intense, intermediate, and short dosing, respectively; the co-primary endpoint of CR rate >15% was not met. Progressive disease (PD)/death rates (number of patients who progressed or died divided by total duration of progression-free survival [PFS] in patient-years; co-primary endpoint) for intense, intermediate, and short dosing were 0.055 (80% confidence interval [CI], 0.014-0.096), 0.102 (80% CI, 0.044-0.160), and 0.206 (80% CI, 0.118-0.295), respectively, translating to a median PFS ≥24 months in all arms (P

Published
2020

5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

7. A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma.

Author

Mian, Hira, Seow, Hsien, Balitsky, Amaris K, Cheung, Matthew C, Gayowsky, Anastasia, Tay, Jason, Wildes, Tanya M, McCurdy, Arleigh, Visram, Alissa, Sandhu, Irwindeep, and Sutradhar, Rinku

Subjects
MULTIPLE myeloma treatment, MORTALITY risk factors, MULTIPLE myeloma, RISK assessment, PATIENT education, PREDICTION models, MEDICAL personnel, RESEARCH funding, HOSPITAL care, TREATMENT effectiveness, RETROSPECTIVE studies, HEART failure, HOSPITAL emergency services, DECISION making, DESCRIPTIVE statistics, ODDS ratio, COMMUNICATION, HEALTH outcome assessment, PSYCHOSOCIAL factors, DISEASE complications, OLD age
Abstract

Developing prognostic tools specifically for patients themselves represents an important step in empowering patients to engage in shared decision-making. Incorporating patient-reported outcomes may improve the accuracy of these prognostic tools. We conducted a retrospective population-based study of transplant-ineligible (TIE) patients with multiple myeloma (MM) diagnosed between January 2007 and December 2018. A multivariable Cox regression model was developed to predict the risk of death within 1-year period from the index date. We identified 2356 patients with TIE MM. The following factors were associated with an increased risk of death within 1 year: age > 80 (HR 1.11), history of heart failure (HR 1.52), "CRAB" at diagnosis (HR 1.61), distance to cancer center (HR 1.25), prior radiation (HR 1.48), no proteosome inhibitor/immunomodulatory therapy usage (HR 1.36), recent emergency department (HR 1.55) or hospitalization (HR 2.13), poor performance status (ECOG 3-4 HR 1.76), and increasing number of severe symptoms (HR 1.56). Model discrimination was high with C-statistic of 0.74, and calibration was very good. To our knowledge, this represents one of the first prognostic models developed in MM incorporating patient-reported outcomes. This survival prognostic tool may improve communication regarding prognosis and shared decision-making among older adults with MM and their health care providers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors

Author

Zhang, Hanbo, primary, Alimohamed, Nimira S., additional, Basappa, Naveen S., additional, Cheng, Tina, additional, Chu, Michael, additional, Cox-Kennett, Nanette, additional, Ernst, D. Scott, additional, Fontaine, Amelie, additional, Ghosh, Sunita, additional, Heng, Daniel Y.C., additional, Littleton, Richard, additional, North, Scott, additional, Railton, Cindy, additional, Sandhu, Irwindeep, additional, Stenson, Trevor H., additional, Stewart, Douglas A., additional, Venner, Christopher, additional, Venner, Peter C., additional, and Kolinsky, Michael P., additional

Published
2023
Full Text
View/download PDF

11. OA-49 Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

Author

Oriol, Albert, primary, Sandhu, Irwindeep, additional, Raab, Marc, additional, White, Darrell, additional, LeBlanc, Richard, additional, Raje, Noopur, additional, Ocio, Enrique, additional, Perrot, Aurore, additional, Facon, Thierry, additional, Rodriguez, Cesar, additional, Waesch, Ralph, additional, Amatangelo, Michael, additional, Zhou, Zehua, additional, Wang, Yue, additional, Civardi, Tiziana, additional, Koo, Philip, additional, Maciag, Paulo, additional, Zhu, Daniel, additional, Katz, Jessica, additional, and Richardson, Paul, additional

Published
2023
Full Text
View/download PDF

12. P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9

Author

Usmani, Saad Z, primary, Mielnik, Michał, additional, Min Byun, Ja, additional, Alonso Alonso, Aránzazu, additional, Abdallah, Al-Ola, additional, Garg, Mamta, additional, Quach, Hang, additional, Min, Chang-Ki, additional, Janowski, Wojciech, additional, Miguel, Enrique Maria Ocio San, additional, Weisel, Katja, additional, Oriol, Albert, additional, Sandhu, Irwindeep, additional, Rodríguez-Otero, Paula, additional, Ramasamy, Karthik, additional, Egger, Jacqueline, additional, Williams, Danaè, additional, MA, Jie, additional, Kaisermann, Morrys, additional, and Hus, Marek, additional

Published
2023
Full Text
View/download PDF

13. An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter.

Author

Lai, Justine, Shang, Chuquan, Chen, Will, Izevbaye, Iyare, Chu, Michael P., Sandhu, Irwindeep, Brandwein, Joseph, Lai, Raymond, and Wang, Peng

Subjects
ACUTE myeloid leukemia, EMBRYONIC stem cells, MYC proteins, SOX2 protein, BIOMARKERS
Abstract

Many patients diagnosed with acute myeloid leukemia (AML) relapse within two years of the initial remission. The biology of AML relapse is incompletely understood, although cancer stem-like (CSL) cells have been hypothesized to be important. To test this hypothesis, we employed SORE6, a reporter designed to detect the transcriptional activity of the embryonic stem cell proteins Oct4 and Sox2, to identify/purify CSL cells in two FLT3-mutated AML cell lines. Both cell lines contained ~10% of SORE6+ cells in the steady state. Compared to SORE6− cells, SORE6+ cells exhibited more characteristics of CSL cells, with significantly higher chemoresistance and rates of spheroid formation. SORE6+ cells had substantially higher expression of Myc and FLT3 proteins, which are drivers of SORE6 activity. Using a mixture of SORE6−/SORE6+ cells that were molecularly barcoded, we generated an in vitro study model for AML relapse. Specifically, after 'in vitro remission' induced by Ara-C, both cell lines regenerated after 13 ± 3 days. Barcode analysis revealed that most of the regenerated cells were derived from the original SORE6+ cells. Regenerated cells exhibited more CSL features than did the original SORE6+ cells, even though a proportion of them lost SORE6 activity. In bone marrow samples from a patient cohort, we found that relapsed blasts expressed significantly higher levels of Myc, a surrogate marker of SORE6 activity, compared to pre-treatment blasts. To conclude, using our in vitro model, we have provided evidence that CSL cells contribute to AML relapse. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.

Author

Usmani, Saad Zafar, primary, Mielnik, Michał, additional, Byun, Ja Min, additional, Alonso, Aránzazu Alonso, additional, Abdallah, Al-Ola A., additional, Garg, Mamta, additional, Quach, Hang, additional, Min, Chang-Ki, additional, Janowski, Wojciech, additional, Ocio, Enrique M., additional, Weisel, Katja, additional, Oriol, Albert, additional, Sandhu, Irwindeep, additional, Rodríguez-Otero, Paula, additional, Ramasamy, Karthik, additional, Egger, Jacqueline L., additional, Williams, Danae, additional, Ma, Jie, additional, Kaisermann, Morrys C., additional, and Hus, Marek, additional

Published
2023
Full Text
View/download PDF

16. Exercise Preferences, Barriers, and Facilitators of Individuals With Cancer Undergoing Chemotherapy Before Stem Cell Transplantation

Author

Purdy, Graeme M., primary, Nanad, Rianna, additional, Ternes, Leslie, additional, Dolgoy, Naomi D., additional, Sellar, Christopher M., additional, Francis, George, additional, Crisp, Nicole, additional, Pituskin, Edith, additional, de Guzman Wilding, Marie, additional, Perry, Sarah, additional, Sandhu, Irwindeep, additional, Venner, Christopher P., additional, and McNeely, Margaret L., additional

Published
2023
Full Text
View/download PDF

18. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Author

Paul, Barry, primary, Liedtke, Michaela, additional, Khouri, Jack, additional, Rifkin, Robert, additional, Gandhi, Mitul D, additional, Kin, Andrew, additional, Levy, Moshe Y, additional, Silbermann, Rebecca, additional, Cottini, Francesca, additional, Sborov, Douglas W, additional, Sandhu, Irwindeep, additional, Villarreal, Lyssa, additional, Murphy, Michael, additional, Gu, Lin, additional, Chen, Ann, additional, Rajakumaraswamy, Nishanthan, additional, and Usmani, Saad Z, additional

Published
2023
Full Text
View/download PDF

19. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Author

Dombret, Hervé, Seymour, John F., Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Noppeney, Richard, Stone, Richard M., Minden, Mark D., McIntyre, Heidi, Songer, Steve, Lucy, Lela M., Beach, C.L., and Döhner, Hartmut

Published
2015
Full Text
View/download PDF

22. Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Author

Berinstein, Neil L, primary, Klein, Gail, additional, Welsh, Katerina, additional, McClure, Rebecca, additional, Forward, Nicholas Allen, additional, Shafey, Mona, additional, Nikonova, Anna, additional, MacDonald, David, additional, Villa, Diego, additional, Sandhu, Irwindeep, additional, Aljama, Mohammed A, additional, and Larouche, Jean-François, additional

Published
2022
Full Text
View/download PDF

23. Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Author

Chu, Michael P., primary, Breckenridge, Zack M., additional, Daly, Andrew, additional, Shafey, Mona, additional, Lewis, Victor A., additional, Desai, Sunil J., additional, Wang, Peng, additional, Brandwein, Joseph, additional, Duggan, Peter, additional, Wilson, Beverly, additional, Thapa, Bindu, additional, Debes-Marun, Carina, additional, and Sandhu, Irwindeep, additional

Published
2022
Full Text
View/download PDF

25. OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Author

Richardson, Paul, primary, Sandhu, Irwindeep, additional, Oriol, Albert, additional, Raab, Marc S., additional, White, Darrell, additional, LeBlanc, Richard, additional, Perrot, Aurore, additional, Ocio, Enrique, additional, Raje, Noopur, additional, Hansen, Charlotte Toftmann, additional, Zhou, Zehua, additional, Civardi, Tiziana, additional, Ghiddi, Alessandro, additional, Katz, Jessica, additional, Peluso, Teresa, additional, and Dimopoulos, Meletios A., additional

Published
2022
Full Text
View/download PDF

26. MM-520 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial

Author

Oriol, Albert, Sandhu, Irwindeep, Raab, Marc S., White, Darrell, LeBlanc, Richard, Raje, Noopur, Ocio, Enrique M., Perrot, Aurore, Facon, Thierry, Rodriguez, Cesar, Waesch, Ralph, Amatangelo, Michael, Zhou, Zehua, Wang, Yue, Civardi, Tiziana, Koo, Phillip, Maciag, Paulo, Zhu, Daniel, Katz, Jessica, and Katz, Paul

Published
2024
Full Text
View/download PDF

27. Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial

Author

Oriol, Albert, Sandhu, Irwindeep, Raab, Marc S., White, Darrell, LeBlanc, Richard, Raje, Noopur, Ocio, Enrique M., Perrot, Aurore, Facon, Thierry, Rodriguez, Cesar, Waesch, Ralph, Amatangelo, Michael, Zhou, Zehua, Wang, Yue, Civardi, Tiziana, Koo, Phillip, Maciag, Paulo, Zhu, Daniel, Katz, Jessica, and Richardson, Paul G.

Published
2024
Full Text
View/download PDF

28. Prise en charge du myelome multiple

Author

Lee, Ann S., Tsang, Roger Y., and Sandhu, Irwindeep

Subjects
Disodium pamidronate, Multiple myeloma -- Management, Company business management, Health
Abstract

1 Le myelome multiple est la deuxieme hemopathie maligne la plus frequente au Canada L'incidence du myelome multiple est de 55 cas par 1 000 000 de personnes au Canada [...]

Published
2021
Full Text
View/download PDF

29. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Author

Moreau, Philippe, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J., Hansson, Markus, Pour, Ludek, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W., Jackson, Sharon R., Stoppa, Anne-Marie, Simpson, David R., Gimsing, Peter, Palumbo, Antonio, Garderet, Laurent, Cavo, Michele, Kumar, Shaji, Touzeau, Cyrille, Buadi, Francis K., Laubach, Jacob P., Berg, Deborah T., Lin, Jianchang, Di Bacco, Alessandra, Hui, Ai-Min, van de Velde, Helgi, and Richardson, Paul G.

Published
2016
Full Text
View/download PDF

30. Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Author

Döhner, Hartmut, primary, Wei, Andrew H., additional, Roboz, Gail J., additional, Montesinos, Pau, additional, Thol, Felicitas R, additional, Ravandi, Farhad, additional, Dombret, Hervé, additional, Porkka, Kimmo, additional, Sandhu, Irwindeep, additional, Skikne, Barry, additional, See, Wendy L., additional, Ugidos, Manuel, additional, Risueño, Alberto, additional, Chan, Esther, additional, Thakurta, Anjan, additional, Beach, C.L., additional, and Lopes de Menezes, Daniel, additional

Published
2021
Full Text
View/download PDF

31. CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Author

Richardson, Paul G., primary, Ocio, Enrique, additional, Raje, Noopur S., additional, Gregory, Tara, additional, White, Darrell, additional, Oriol, Albert, additional, Sandhu, Irwindeep, additional, Raab, Marc-Steffen, additional, LeBlanc, Richard, additional, Rodriguez, Cesar, additional, Trudel, Suzanne, additional, Wäsch, Ralph, additional, Perrot, Aurore, additional, Bahlis, Nizar J., additional, Zhou, Zehua, additional, Lamba, Manisha, additional, Amatangelo, Michael, additional, Civardi, Tiziana, additional, Katz, Jessica, additional, Maciag, Paulo, additional, Peluso, Teresa, additional, and Dimopoulos, Meletios A., additional

Published
2021
Full Text
View/download PDF

33. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Author

Döhner, Hartmut, primary, Symeonidis, Argiris, additional, Deeren, Dries, additional, Demeter, Judit, additional, Sanz, Miguel A., additional, Anagnostopoulos, Achilles, additional, Esteve, Jordi, additional, Fiedler, Walter, additional, Porkka, Kimmo, additional, Kim, Hee-Je, additional, Lee, Je-Hwan, additional, Usuki, Kensuke, additional, D'Ardia, Stefano, additional, Won Jung, Chul, additional, Salamero, Olga, additional, Horst, Heinz-August, additional, Recher, Christian, additional, Rousselot, Philippe, additional, Sandhu, Irwindeep, additional, Theunissen, Koen, additional, Thol, Felicitas, additional, Döhner, Konstanze, additional, Teleanu, Veronica, additional, DeAngelo, Daniel J., additional, Naoe, Tomoki, additional, Sekeres, Mikkael A., additional, Belsack, Valerie, additional, Ge, Miaomiao, additional, Taube, Tillmann, additional, and Ottmann, Oliver G., additional

Published
2021
Full Text
View/download PDF

34. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Author

Richardson, Paul G., primary, Kumar, Shaji K., additional, Masszi, Tamás, additional, Grzasko, Norbert, additional, Bahlis, Nizar J., additional, Hansson, Markus, additional, Pour, Luděk, additional, Sandhu, Irwindeep, additional, Ganly, Peter, additional, Baker, Bartrum W., additional, Jackson, Sharon R., additional, Stoppa, Anne-Marie, additional, Gimsing, Peter, additional, Garderet, Laurent, additional, Touzeau, Cyrille, additional, Buadi, Francis K., additional, Laubach, Jacob P., additional, Cavo, Michele, additional, Darif, Mohamed, additional, Labotka, Richard, additional, Berg, Deborah, additional, and Moreau, Philippe, additional

Published
2021
Full Text
View/download PDF

37. Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Author

Kotb, Rami, White, Darrell, Bhella, Sita, McCurdy, Arleigh, Sandhu, Irwindeep, Mian, Hira, Stakiw, Julie, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, and Reece, Donna

Published
2023
Full Text
View/download PDF

38. Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

Author

Richardson, Paul G., Sandhu, Irwindeep, Hofmeister, Craig C., Orlowski, Robert Z., White, Darrell, Belotti, Angelo, Toftmann Hansen, Charlotte, Raje, Noopur S., Chow, Tracy T., Zhou, Zehua, Civardi, Tiziana, Koo, Phillip, Zhu, Yue, Katz, Jessica, and Oriol, Albert

Published
2023
Full Text
View/download PDF

40. Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Author

Paul, Barry, Minarík, Jirí, Cottini, Francesca, Gasparetto, Cristina, Khouri, Jack, Gandhi, Mitul, Hillengass, Jens, Levy, Moshe, Liedtke, Michaela, Manda, Sudhir, Sandhu, Irwindeep, Sborov, Douglas, Spicka, Ivan, Usmani, Saad Z, Gu, Lin, Robeson, Michelle, Murphy, Michael, Renard, Camille, Chen, Christine, and Pour, Luděk

Published
2023
Full Text
View/download PDF

41. Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Author

Landgren, Ola, Chari, Ajai, Cohen, Yael C., Spencer, Andrew, Voorhees, Peter M., Sandhu, Irwindeep, Jenner, Matthew W., Smith, Dean, Cavo, Michele, van de Donk, Niels WCJ, Beksac, Meral, Moreau, Philippe, Goldschmidt, Hartmut, Sha, Linlin, Li, Liang, Rousseau, Els, Dennis, Robyn, Carson, Robin, and Hofmeister, Craig C.

Published
2023
Full Text
View/download PDF

44. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

Author

Venner, Christopher P., primary, LeBlanc, Richard, additional, Sandhu, Irwindeep, additional, White, Darrell, additional, Belch, Andrew R., additional, Reece, Donna E., additional, Chen, Christine, additional, Dolan, Sean, additional, Lalancette, Marc, additional, Louzada, Martha, additional, Kew, Andrea, additional, McCurdy, Arleigh, additional, Monteith, Bethany, additional, Reiman, Tony, additional, McDonald, Gail, additional, Sherry, Max, additional, Gul, Engin, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2021
Full Text
View/download PDF

46. Prognostic impact of NPM1and FLT3mutations in patients with AML in first remission treated with oral azacitidine

Author

Döhner, Hartmut, Wei, Andrew H., Roboz, Gail J., Montesinos, Pau, Thol, Felicitas R., Ravandi, Farhad, Dombret, Hervé, Porkka, Kimmo, Sandhu, Irwindeep, Skikne, Barry, See, Wendy L., Ugidos, Manuel, Risueño, Alberto, Chan, Esther T., Thakurta, Anjan, Beach, C.L., and Lopes de Menezes, Daniel

Abstract

•Patients in remission treated with Oral-AZA had better OS and RFS vs placebo regardless of NPM1or FLT3mutational status at AML diagnosis.•Oral-AZA conferred OS and/or RFS benefits in patients with favorable (NPM1mut, no MRD) or adverse (FLT3mut, MRD+) prognostic AML features.

Published
2022
Full Text
View/download PDF

47. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Author

Wei, Andrew H., primary, Döhner, Hartmut, additional, Pocock, Christopher, additional, Montesinos, Pau, additional, Afanasyev, Boris, additional, Dombret, Hervé, additional, Ravandi, Farhad, additional, Sayar, Hamid, additional, Jang, Jun-Ho, additional, Porkka, Kimmo, additional, Selleslag, Dominik, additional, Sandhu, Irwindeep, additional, Turgut, Mehmet, additional, Giai, Valentina, additional, Ofran, Yishai, additional, Kizil Çakar, Merih, additional, Botelho de Sousa, Aida, additional, Rybka, Justyna, additional, Frairia, Chiara, additional, Borin, Lorenza, additional, Beltrami, Germana, additional, Čermák, Jaroslav, additional, Ossenkoppele, Gert J., additional, La Torre, Ignazia, additional, Skikne, Barry, additional, Kumar, Keshava, additional, Dong, Qian, additional, Beach, C.L., additional, and Roboz, Gail J., additional

Published
2020
Full Text
View/download PDF

48. Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Author

Dohner, Hartmut, primary, Wei, Andrew, additional, Montesinos, Pau, additional, Dombret, Hervé, additional, Ravandi, Farhad, additional, Sayar, Hamid, additional, Porkka, Kimmo, additional, Sandhu, Irwindeep, additional, Passamonti, Francesco, additional, Pane, Fabrizio, additional, Robak, Tadeusz, additional, Falantes, Jose F., additional, Schuh, Andre C., additional, Ossenkoppele, Gert J., additional, La Torre, Ignazia, additional, Skikne, Barry, additional, Kumar, Keshava, additional, Dong, Qian, additional, Beach, C. L., additional, and Roboz, Gail J., additional

Published
2020
Full Text
View/download PDF

49. High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) for relapsed metastatic germ cell tumors (mGCTs): The Alberta experience from 2001 to 2018.

Author

Zhang, Hanbo, primary, Alimohamed, Nimira S., additional, Basappa, Naveen S., additional, Cheng, Tina, additional, Chu, Michael, additional, Cox-Kennett, Nanette, additional, Ernst, D. Scott, additional, Fontaine, Amelie, additional, Ghosh, Sunita, additional, Heng, Daniel Yick Chin, additional, Littleton, Richard, additional, North, Scott A., additional, Railton, Cindy, additional, Sandhu, Irwindeep, additional, Stewart, Douglas Allan, additional, Venner, Chris, additional, Venner, Peter M., additional, and Kolinsky, Michael Paul, additional

Published
2020
Full Text
View/download PDF

50. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Author

Wei, Andrew H., primary, Döhner, Hartmut, additional, Pocock, Christopher, additional, Montesinos, Pau, additional, Afanasyev, Boris, additional, Dombret, Hervé, additional, Ravandi, Farhad, additional, Sayar, Hamid, additional, Jang, Jun Ho, additional, Porkka, Kimmo, additional, Selleslag, Dominik, additional, Sandhu, Irwindeep, additional, Turgut, Mehmet, additional, Giai, Valentina, additional, Ofran, Yishai, additional, Kizil Cakar, Merih, additional, Botelho de Sousa, Aida, additional, Rybka, Justyna, additional, Frairia, Chiara, additional, Borin, Lorenza, additional, Beltrami, Germana, additional, Cermak, Jaroslav, additional, Ossenkoppele, Gert J., additional, La Torre, Ignazia, additional, Skikne, Barry, additional, Kumar, Keshava, additional, Dong, Qian, additional, Beach, CL, additional, and Roboz, Gail J., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results